OncoMatch/Clinical Trials/NCT07182279
Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer
Is NCT07182279 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies Brachytherapy for prostate cancer (adenocarcinoma).
Treatment: Brachytherapy — This is a Phase I/II trial evaluating the effectiveness of adding neoadjuvant HDR-B prior to RALP for HR-PCa patients with selective AAB for decipher high risk or pathologically node positive patients. Patients with newly diagnosed, histologically confirmed, non-metastatic, HR-PCa who are scheduled to receive RALP will be eligible to participate in the study.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Disease stage
Required: Stage T2C, ≥T3A (AJCC 8th Edition)
Clinical or radiographic stage ≥T3a per AJCC (American Joint Committee on Cancer) 8th Edition Staging Manual and/or At least two out of four of the following: ... clinical stage = T2b/T2c
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: androgen deprivation therapy
Exception: finasteride if discontinued > 3 months prior to enrollment
No prior androgen deprivation therapy in the past 6 months. History of androgen deprivation therapy within the past 6 months (except finasteride if discontinued > 3 mo. prior to enrollment).
Cannot have received: pelvic radiation therapy
History of prior pelvic radiation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Houston Methodist · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07182279 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior androgen deprivation therapy, pelvic radiation therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage T2C or ≥T3A is required.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages